Published August 25, 2020
| Version v1
Patent
Open
Treatment of TNF- alpha cytotoxicity
Contributors
Patent applicant:
Description
Provided herein is technology relating to treating and/or ameliorating TNFα cytotoxicity and particularly, but not exclusively, to compositions, methods, and kits for specifically modulating BCL-2-associated death promoter (BAD) activity, for example, by modulating the activity of Src and/or p190GAP.
Files
US10751324.pdf
Files
(3.8 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:c346e549b5bd0b796dfb4091faea4b54
|
3.8 MB | Preview Download |
Additional details
Identifiers
- Patent number
- US 10751324 B2
- Patent application number
- US 201716329499 A
- Other
- oai:uchicago.tind.io:7382
Dates
- Patent filed
-
2017-09-01